PTC Therapeutics (PTCT) said late Wednesday the US Food and Drug Administration has accelerated approval of Kebilidi, the company's gene therapy for the treatment of aromatic L-amino acid decarboxylase deficiency.

The therapy, also called eladocagene exuparvovec-tneq, is for the treatment of children and adults across the full spectrum of the rare, life-shortening genetic deficiency, the company said.

Treatment centers have already been identified and surgeons already trained to administer the treatment, which is injected directly into the brain, the company said.

The drug received accelerated approval based on results of an ongoing clinical trial, the company said.

Shares of the company were up 5% in Wednesday's after-hours activity.

Price: 46.23, Change: +2.20, Percent Change: +5.00